What's in Bharat Biotech International Limited's pipeline?

Bharat Biotech International Limited has 10 drugs in our index: 0 marketed, 0 filed, 9 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Bharat Biotech International Limited's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Merck Sharp & Dohme LLC, Sinovac Biotech Co., Ltd, Jiangsu Province Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases (NIAID).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bharat-biotech-international-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Bharat Biotech International Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bharat Biotech International Limited pipeline: 0 marketed, 0 filed, 9 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 9 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
BBV154 Intranasal Vaccine	BBV154 Intranasal Vaccine	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
ROTAVAC 5C -F2	ROTAVAC 5C -F2	phase 3	Vaccine		Infectious Diseases
THR-100	THR-100	phase 3	COVID-19 vaccine	SARS-CoV-2 spike protein	Infectious disease
Hillchol vaccine	Hillchol vaccine	phase 3	Therapeutic vaccine		Cardiovascular
BBV154(Intranasal) & covaxin	BBV154(Intranasal) & covaxin	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
ROTAVAC 5C -F1	ROTAVAC 5C -F1	phase 3	Live attenuated rotavirus vaccine		Immunology / Infectious Disease
Intramuscular vaccine COVAXIN	Intramuscular vaccine COVAXIN	phase 3	Inactivated viral vaccine		Immunology / Infectious Disease
ORV 116E	ORV 116E	phase 3	Live attenuated vaccine		Immunology / Infectious Disease
Covishield	Covishield	phase 3			Other

Therapeutic area mix

Immunology / Infectious Disease · 5
Cardiovascular · 1
Infectious Diseases · 1
Infectious disease · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Sinovac Biotech Co., Ltd · 3 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes
National Institute of Allergy and Infectious Diseases (NIAID) · 3 shared drug classes
Sanofi Pasteur, a Sanofi Company · 3 shared drug classes
Green Cross Corporation · 3 shared drug classes
Valneva Austria GmbH · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bharat Biotech International Limited:

Cite this brief

Drug Landscape (2026). Bharat Biotech International Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bharat-biotech-international-limited. Accessed 2026-05-17.